Related Experiment Video
Updated: Nov 9, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Sutimlimab in Cold Agglutinin Disease
Alexander Röth1, Wilma Barcellini1, Shirley D'Sa1
1From the Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany (A.R.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Milan, Italy (W.B.); the Centre for Waldenström's Macroglobulinaemia and Related Conditions, University College London Hospitals National Health Service Foundation Trust, London (S.D.); the Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama, Japan (Y.M.); the Division of Hematology, MedStar Georgetown University Hospital, Washington, DC (C.M.B.); the Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris-Est Créteil, Créteil, France (M.M.); the Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston (D.J.K.), Bioverativ, Cambridge (J.F.), and Sanofi, Waltham (X.J., S.L., C.R., J.M.-A., W.H.) - all in Massachusetts; the Department of Clinical Pharmacology, Medical University of Vienna, Vienna (B.J.); and the Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen (T.H.A.T.), and the Department of Research and Innovation, Haugesund Hospital, Haugesund (S.B.) - both in Norway.
Sutimlimab effectively treats cold agglutinin disease by inhibiting the complement pathway, leading to increased hemoglobin and reduced fatigue in patients. This rare autoimmune hemolytic anemia treatment shows promising results in clinical trials.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Cold agglutinin disease is a rare autoimmune hemolytic anemia.
- Hemolysis is caused by activation of the classic complement pathway.
- Sutimlimab is a monoclonal antibody targeting the C1s protein to inhibit this pathway.
Purpose of the Study:
- To assess the efficacy and safety of intravenous sutimlimab in patients with cold agglutinin disease.
- To evaluate sutimlimab's effect on hemoglobin levels, transfusion needs, and fatigue.
- To measure the inhibition of the classic complement pathway.
Main Methods:
- A 26-week multicenter, open-label, single-group study.
- 24 patients with cold agglutinin disease received intravenous sutimlimab.
- Primary endpoint: normalization or significant increase in hemoglobin without transfusions.
Main Results:
- 54% of patients met the primary endpoint.
- Mean hemoglobin increase of 2.6 g/dL; maintained >11 g/dL.
- 71% avoided transfusions; significant fatigue reduction observed.
Conclusions:
- Sutimlimab rapidly halts hemolysis in cold agglutinin disease.
- Treatment increases hemoglobin levels and reduces fatigue.
- Selective inhibition of the complement pathway is effective.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:27Tumor Immunotherapy